Navigation Links
ALS TDI Completes Gene Expression Profile of Lou Gehrig's Disease in Mice
Date:10/2/2007

Largest Target-Discovery Program Aimed at New Treatments for Fatal Disease

CAMBRIDGE, Mass., Oct. 2 /PRNewswire/ -- The ALS Therapy Development Institute (ALS TDI) today announced that it has completed the first phase of a comprehensive gene-expression database for ALS with the profiling of the SOD1 mouse model of amyotrophic lateral sclerosis -- ALS, or Lou Gehrig's disease. The second phase, profiling of human samples, is scheduled for completion by February of 2008. This study is part of the largest known target-discovery program aimed at developing new treatments for the fatal neuromuscular disease.

"This dataset is the foundation that will enable scientists at ALS TDI to understand the biological mechanisms associated with disease progression," said Steve Perrin, Ph.D., chief scientific officer at ALS TDI. "Additional gene expression profiling and proteomics analysis from other mouse models of neurodegeneration, as well as human samples collected at ALS clinics, will help us focus on the most relevant biological pathways to target for drug development."

The gene-profiling study involved looking at which genes are turned on over a period of time in various tissues of the SOD1 mouse. Comprising more than 250 samples from four different tissues, the comprehensive database reflects gene expression from eight time points during disease onset and progression. Scientists at Gene Logic Inc., of Gaithersburg, Md., isolated total RNA from the tissue samples, generated high quality genomic data using the Affymetrix GeneChip(R), and used their expert bioanalytical capabilities to identify the activated genes implicated in ALS.

"The assembly of this data set is an important milestone. We could not have gotten to this point without the critical support of Congressman Capuano, Senator Kennedy, the Department of Defense, the MDA and the nearly 250 families that have invested in our unique approach," said Sean Scott, president of ALS TDI, "However,
'/>"/>

SOURCE ALS Therapy Development Institute
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
6. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
7. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
8. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
9. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Antipsychotic Iloperidone Results Show Favorable Akathisia Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets ... Drugs - Global Strategic Business Report" report to their ... for Human Growth Hormone Drugs in US$ Million by the ... The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ...
(Date:8/19/2014)... , Aug. 19, 2014  Boehringer Ingelheim ... Administration (FDA) accepted for review the New Drug ... tiotropium and olodaterol delivered via the Respimat ® ... once-daily maintenance treatment of airflow obstruction in patients ... bronchitis and/or emphysema. Tiotropium + olodaterol FDC will ...
(Date:8/19/2014)... Aug. 19, 2014  Stryker Corporation,s Orthopaedics Division, the Official ... is bringing its message of joint health to golf fans ... this week at The Barclays.  The company,s fan destination ... Spectator Village near the 17 th fairway at the ... on Thursday, August 21 st .    At ...
Breaking Medicine Technology:Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 2Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 3Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 4Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 5Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 6Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 7Boehringer Ingelheim Announces U.S. Filing for the Fixed-Dose Combination Tiotropium Plus Olodaterol for Patients with COPD 8Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5
... 31, 2011 Boston Scientific Corporation (NYSE: ... Food and Drug Administration (FDA) has approved its ... and delivery of diagnostic, embolic and therapeutic materials ... be used by interventional radiologists for minimally invasive ...
... Endologix, Inc. (Nasdaq: ELGX ), ... announced today the publication of favorable clinical results ... of abdominal aortic aneurysm (EVAR).  The peer-reviewed article ... trial, with successful aneurysm exclusion in all patients, ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 2Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 3Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System 4Endologix Announces Favorable Clinical Results for Nellix Technology 2Endologix Announces Favorable Clinical Results for Nellix Technology 3
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 The ... PM360, a leading health-marketing industry trade magazine, will honor ... the Trailblazer Awards are given to outstanding companies, marketers ... to offer. , “We are proud to announce ... call to entries with double the number of submissions ...
(Date:8/20/2014)... Botanica Day Spa ... the new and popular stem cell line from ... and wrinkles and naturally repairs the skin. The ... new service by offering clients a complimentary dermaplaning ... facial. , Pevonia® continues to be a global ...
(Date:8/20/2014)... chosen by Plymouth University to be an official charity ... to raise awareness of, and funding for, scientific research ... patients. , A range of events and activities organised ... and members of staff and students, as well as ... and volunteer. The involvement of the wider community across ...
(Date:8/20/2014)... 2014 If old age is a disease ... it. With extensive research on HGH and stem cells technology, ... have perfected the art of rubbing off decades from your ... look with their revolutionary anti-aging hormone therapy and regenerative medicine. ... fountain of youth, the MD of MetroMD, Dr Alex Martin ...
(Date:8/20/2014)... Jersey (PRWEB) August 20, 2014 New ... the needs of an estimated tens of thousands of ... the new Bill A3525—a bill that would expand the ... grow their own cannabis—earlier this summer by State Assemblywoman ... for medicinal quality marijuana is growing. , To help ...
Breaking Medicine News(10 mins):Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3
... ... ways to make Obamacare palatable to Americans, a new poll conducted by ... which was conducted January 19-21, shows that an overwhelming majority of Americans ... versions of Obamacare. The Poll also finds that nearly all Americans ...
... NORTH HOLLYWOOD, Calif. , Feb. 2 IPC The Hospitalist Company, Inc. (Nasdaq: IPCM ), ... Bank 2010 Small and Mid Cap Conference held in Naples, FL.   , ... Jeff Taylor, President and COO, Date: ... 10:00 a.m. Eastern, Place: ...
... to inhaling nearly 3 more, study finds , TUESDAY, Feb. ... with directly inhaling cigarette smoke, smokers also face significant risk ... published online Jan. 29 in Environmental Health , challenges ... by secondhand smoke is negligible. , The study focused on ...
... ... distribution agreement to provide GuardRFID’s Active RFID platform to its Healthcare, Government and Industrial ... (PRWEB) ... VT Milcom of Virginia Beach, Va. to provide its next generation RFID platform to ...
... RANCHO CORDOVA, Calif. , Feb. 2 VSP ... eyewear through innovative business solutions and quality vision products, today ... financial officer. Ball will replace former vice president and CFO ... and report to chief executive officer, Rob Lynch . ...
... , New online hospital ratings put infection rates ... YONKERS, N.Y. , Feb. 2 Hospitals in ... of how well their intensive care units (ICUs) prevent central-line bloodstream infections, ... is largely preventable.  On February 2 , www.ConsumerReportsHealth.org will ...
Cached Medicine News:Health News:79% of Voters Say Obamacare Marriage Penalty "Unfair" 2Health News:79% of Voters Say Obamacare Marriage Penalty "Unfair" 3Health News:IPC The Hospitalist Company, Inc. to Present at Deutsche Bank 2010 Small and Mid Cap Conference 2Health News:Guard RFID Solutions Inc. and VT Milcom Enter into Distribution Agreement 2Health News:VSP Global Appoints New Chief Financial Officer 2Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 2Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 3Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 4Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 5Health News:Consumer Reports Health: Central-Line Infection Rates in Tampa-St. Petersburg Area Hospitals Vary Dramatically 6
... Nebulizer Prefilled 750ML Sterile H 2 O ... with sterile water for inhalation, these humidifier systems ... which makes a round opening for secure attachment ... designed to help prevent particulate from reaching oxygen ...
... 35%-100% FIO2, ,Empty Nebulizer 002002 has ... It has ports for a feed set ... 5007P and 5207 have FIO2 settings adjustable ... slip-on heaters are also available to provide ...
... , One device provides both ... from a single gas source , ... the number of SKUs dedicated to ... inconvenience of double or wye set ...
MISTY OX® Hi-Fi Nebulizer...
Medicine Products: